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CLINICAL AND POPULATION STUDIES
PAR1 (Protease-Activated Receptor 1) Pepducin 
Therapy Targeting Myocardial Necrosis in Coronary 
Artery Disease and Acute Coronary Syndrome 
Patients Undergoing Cardiac Catheterization
A Randomized, Placebo-Controlled, Phase 2 Study
Athan Kuliopulos , Paul A. Gurbel , Jeffrey J. Rade, Carey D. Kimmelstiel, Susan E. Turner, Kevin P. Bliden, Elizabeth K. Fletcher, 
Daniel H. Cox, Lidija Covic ; on behalf of the TRIP-PCI Investigators
OBJECTIVE: Arterial thrombosis leading to ischemic injury worsens the prognosis of many patients with cardiovascular disease. 
PZ-128 is a first-in-class pepducin that reversibly inhibits PAR1 (protease-activated receptor 1) on platelets and other 
vascular cells by targeting the intracellular surface of the receptor. The TRIP-PCI (Thrombin Receptor Inhibitory Pepducin in 
Percutaneous Coronary Intervention) trial was conducted to assess the safety and efficacy of PZ-128 in patients undergoing 
cardiac catheterization with intent to perform percutaneous coronary intervention.
APPROACH AND RESULTS: In this randomized, double-blind, placebo-controlled, phase 2 trial, 100 patients were randomly assigned 
(2:1) to receive PZ-128 (0.3 or 0.5 mg/kg), or placebo in a 2-hour infusion initiated just before the start of cardiac catheterization, 
on top of standard oral antiplatelet therapy. Rates of the primary end point of bleeding were not different between the combined 
PZ-128 doses (1.6%, 1/62) and placebo group (0%, 0/35). The secondary end points of major adverse coronary events at 30 
and 90 days did not significantly differ but were numerically lower in the PZ-128 groups (0% and 2% in the PZ-128 groups, 
6% and 6% with placebo, p=0.13, p=0.29, respectively). In the subgroup of patients with elevated baseline cardiac troponin 
I, the exploratory end point of 30-day major adverse coronary events + myocardial injury showed 83% events in the placebo 
group versus 31% events in the combined PZ-128 drug groups, an adjusted relative risk of 0.14 (95% CI, 0.02–0.75); P=0.02.
CONCLUSIONS: In this first-in-patient experience, PZ-128 added to standard antiplatelet therapy appeared to be safe, well 
tolerated, and potentially reduced periprocedural myonecrosis, thus providing the basis for further clinical trials.
REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02561000.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: acute coronary syndrome ◼ coronary artery disease ◼ myocardial infarction ◼ percutaneous coronary intervention ◼ troponin
Cardiovascular disease remains the major underly-ing cause of death in the United States and Europe with 41% to 44% of these deaths due to ischemic 
coronary heart disease.1,2 Despite highly prevalent use of 
antithrombotics and lipid-lowering agents, recurrent ath-
erothrombosis remains an area of major unmet medical 
need with a 5-year mortality rate of 36% to 47% after a 
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Patients with suspected acute coronary syndrome (ACS) 
admitted to hospital emergency departments with myo-
cardial injury (myonecrosis) identified by cardiac troponin 
assay will experience a 17% to 19% rate of MI or death 
from cardiovascular causes within 1 year.3
Antiplatelet therapy plays a central role in preventing 
thrombosis and recurrent MI in ACS and high-risk coro-
nary artery disease (CAD), and nonculprit lesion MI.4–6 
Platelets regulate normal hemostasis after injury and play a 
dominant role in arterial thrombus formation. Acute plaque 
rupture exposes subendothelial collagen which promotes 
platelet activation and formation of thrombi at the site of 
vascular damage. Compared with clopidogrel, more potent 
ADP (adenosine diphosphate) receptor inhibitors, such 
as prasugrel, ticagrelor, and cangrelor, reduce the risk of 
ischemic events by 20% in patients with ACS.6,7 However, 
intensified blockade of P2Y12 with these agents is associ-
ated with greater bleeding and other side effects, such as 
dyspnea.8 Many patients taking these drugs still sustain 
thrombotic events and would benefit from therapeutics 
that suppress both platelet activation and myonecrosis.
Parenteral PAR1 receptor inhibition is emerging as a 
new therapeutic strategy to regulate thrombin-induced 
platelet activation during percutaneous coronary inter-
vention (PCI) and ACS.9 Currently, there are no approved 
PAR1 inhibitors for treatment of ACS or patients under-
going PCI. The oral PAR1 inhibitor vorapaxar10–12 was 
associated with a reduction in risk of MI, stroke, cardio-
vascular death, and revascularization in stable patients 
with a previous MI or peripheral arterial disease and was 
approved by the Food and Drug Administration for these 
2 indications. The limitations of vorapaxar include a very 
long pharmacodynamic half-life of ≥4 weeks and oral 
administration leading to a slow onset of pharmacody-
namic effects during the PCI procedure and an elevated 
risk of bleeding.13 There have been no reports of fast-
acting parenteral PAR1 blockade in humans. The ability 
to rapidly and reversibly inhibit PAR1 signaling by a par-
enteral strategy would be an ideal in the high-risk patient 
undergoing PCI.
PZ-128 is a first-in-class pepducin inhibitor of PAR1 
intended for use in patients with CAD/ACS undergo-
ing coronary interventions.14,15 Pepducins are lipidated 
peptides which target the cytoplasmic surface of their 
cognate receptor.16,17 Pepducin technology comprises 
a short peptide derived from a GPCR (G-protein–cou-
pled receptor) intracellular loop, tethered to a hydro-
phobic moiety. This structure allows the PZ-128 to 
anchor in the cell membrane lipid bilayer, rapidly flip 
across to the inner leaflet in a reversible manner, and 
target the GPCR/G-protein interface to modulate cou-
pling of receptor with G protein (Figure 1).18 PZ-128 
has shown significant efficacy in a number of pre-
clinical models including suppressing acute arterial 
thrombosis in guinea pigs and nonhuman primates and 
reducing atherosclerotic plaque burden in mice.14,19 
Here, we report the results of the TRIP-PCI clinical 
study (Thrombin Receptor Inhibitory Pepducin in PCI), 
which evaluated 2 dose levels of PZ-128 (0.3 and 0.5 
mg/kg) compared with a placebo in adult patients with 
CAD/ACS referred for cardiac catheterization and PCI. 
The objectives were to assess the safety, tolerability, 
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndromes
CABG coronary artery bypass grafting
CAD coronary artery disease




NSTEMI  non–ST-segment–elevation myocardial 
infarction
PAR1 protease-activated receptor 1
PCI percutaneous coronary intervention
TIMI Thrombolysis In Myocardial Infarction
TRIP-PCI  Thrombin Receptor Inhibitory Pepducin 
in Percutaneous Coronary Intervention
Highlights
• A ceiling of net clinical benefit associated with aspi-
rin and P2Y12 receptor blockers indicates a need for 
targeting alternative pathways to prevent life-threat-
ening ischemic complications in patients with severe 
coronary artery disease.
• Thrombin, the most potent mediator of both hemo-
stasis and thrombosis, targets PAR1 (protease-
activated receptor 1), but there are no approved 
PAR1 inhibitors for treatment of acute coronary 
syndromes or patients undergoing percutaneous 
coronary intervention.
• Thrombin Receptor Inhibitory Pepducin in 
Percutaneous Coronary Intervention is the first ran-
domized, placebo-controlled trial in humans to test 
the safety and efficacy of a pepducin compound 
which targets the inside surface of a G-protein–
coupled receptor, namely PAR1.
• PZ-128 was well tolerated in coronary artery dis-
ease and acute coronary syndromes patients under-
going percutaneous coronary intervention and may 
confer a potential benefit in protecting against myo-
cardial injury along with suppressing platelet throm-
bus formation in higher-risk patients.
• Consistent with its mechanism of interacting with 
the PAR1 receptor on the inside surface of platelets, 
the pepducin effects were prolonged with >50% 
inhibition at 24 hours but were reversible and could 
be overcome with higher amounts of PAR1 agonist 
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and efficacy of intravenous PZ-128 pepducin in this 
phase 2 clinical trial.
MATERIALS AND METHODS
Study Design
The data that support the findings of this study are available 
from the corresponding author upon reasonable request. 
The TRIP-PCI trial was a prospective, multicenter ran-
domized, parallel-group, double-blind, placebo-controlled 
trial to evaluate the safety and efficacy of a single, intrave-
nous infusion of PZ-128 at 2 dose levels (0.3 or 0.5 mg/kg) 
in adults with CAD/ACS undergoing nonemergent cardiac 
catheterization ± PCI. The TRIP-PCI trial was conducted at 3 
clinical sites in the United States.
Institutional review board approval was obtained before 
study initiation at each clinical site. The study was conducted 
in accordance with the Declaration of Helsinki, International 
Conference on Harmonization E6 guidelines for Good Clinical 
Practice, and applicable US Food and Drug Administration 
regulations. All of the study patients provided written informed 
consent, including US Health Insurance Portability and 
Accountability Act (1996) authorization, before participation 
in the study.
Participant Eligibility
Eligible patients included men and women (18 years or older) 
with stable CAD (stable angina), no angina with abnormal stress 
test/imaging (other), unstable angina (negative or unknown 
cardiac biomarker status), or non–ST-segment–elevation 
myocardial infarction (NSTEMI; positive cardiac biomarker) 
according to the American College of Cardiology Foundation/
American Heart Association20 who were scheduled to undergo 
nonemergent coronary angiography with the intention to 
perform PCI if clinically indicated. Patients with any history of 
stroke or transient ischemic attack were excluded. A compre-
hensive list of inclusion and exclusion criteria is provided in the 
Data Supplement.
Randomization and Masking
Eligible patients were randomized within a 14-day screen-
ing interval before cardiac catheterization, in order of enroll-
ment via a remote, web-based software platform. Patients 
were randomly assigned to one of 4 parallel groups (2:2:1:1) 
to receive either PZ-128 0.3 mg/kg, PZ-128 0.5 mg/kg, pla-
cebo 0.3 mg/kg, or placebo 0.5 mg/kg as a single infusion 
of Investigational Product, based on a computer-generated 
randomization scheme provided by an independent statistician. 
Randomization was stratified according to 2 variables: clinical 
site and urgency of the cardiac catheterization procedure (elec-
tive versus urgent).
Participating patients, clinical site investigators and person-
nel, and the sponsor were blinded to treatment assignments, 
with the exception of designated clinical site investigational 
pharmacists who received the patients’ study drug assign-
ments through a restricted role login within a web-response 
system and prepared the parenteral solutions of PZ-128 
or matching placebo. The pepducin was reconstituted from 
lyophilized powder (48 mg/vial) as micellular nanoparticles 
with sterile water for injection. Weight-adjusted dosing vol-
umes were diluted into a 250 mL sterile bag of 5% dextrose 
injection USP resulting in colorless liquids which could not be 
visually distinguished from placebo.
Study Protocol
On the day of the procedure, all patients received a dose of aspi-
rin orally (81–325 mg) before the initiation of the study drug, 
which was to commence between 0 and 60 minutes before 
the start of coronary angiography. Regardless of whether a PCI 
Figure 1. PZ-128.
A, The activated structure of PAR1 (protease-activated receptor 1; on-state: chartreuse) bound to intracellular G protein was modeled on 
the x-ray structure of the β2-adrenergic receptor (purple) bound to Gs (red) and the x-ray structure of PAR1 in the (B) off-state (orange).33 
PZ-128 (white), is a N-palmitoylated peptide (palmitate-KKSRALF) derived from the juxtamembrane region of the third intracellular (i3) loop-
transmembrane 6 segments of PAR1.14 PZ-128 rapidly flips across the lipid bilayer to the intracellular surface where it specifically inhibits 
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was performed, the entire 2-hour study drug infusion was to 
be given without modification to the dose or rate of admin-
istration. Allowances were made for a temporary interruption 
of the infusion up to 1 hour or discontinuation of the study 
drug if clinically indicated. Background treatment was provided 
at the discretion of the local clinical investigator according to 
the current standard-of-care guidelines. If patients underwent 
a PCI (defined as guidewire crossing the lesion), investigators 
administered unfractionated or low-molecular-weight heparin 
anticoagulant (direct thrombin inhibitors were not permitted) 
followed by a loading dose of an oral P2Y12 inhibitor per inves-
tigator preference (clopidogrel, prasugrel, or ticagrelor). Food 
and Drug Administration-approved bare metal, drug-eluting, 
or biodegradable coronary stents were implanted. A GP (gly-
coprotein)IIb/IIIa inhibitor was allowed only as a rescue or 
bailout therapy to manage thrombotic complications arising 
during PCI. Patients for whom PCI was not indicated or per-
formed that day based upon the coronary angiography findings 
were managed medically or recommended for coronary artery 
bypass grafting (CABG). Following cardiac catheterization ± 
PCI, investigators employed maintenance antiplatelet therapy 
with aspirin and oral P2Y12 inhibitor. cTnI (Cardiac troponin I) 
biomarker blood samples were collected at predose, 2 hours, 4 
to 6 hours, discharge (same day) or 24 hours, and 14 days after 
the start of study drug and measured (Abbott Architect assay; 
99th URL=0.028 ng/mL, % coefficient of variation=14.0, limit 
of detection=0.01 ng/mL) at a central, certified clinical chem-
istry lab. Patients were seen for an outpatient study visit at 14 
days and were contacted via telephone at 30 and 90 days after 
administration of the study drug for clinical end points (efficacy 
and safety) and adverse outcomes.
Study End Points
The primary end point was the incidence of TIMI (Thrombolysis 
In Myocardial Infarction) major or minor bleeding not related 
to CABG up to 30 days after study drug treatment. Secondary 
safety end points included TIMI minimal bleeding, clinically sig-
nificant bleeding, and TIMI bleeding related to CABG up to 30 
days. Other safety outcome measures included spontaneously 
reported adverse events and clinical and laboratory assess-
ments, including vital signs, ECGs, physical examination, blood 
chemistry, hematology, and coagulation monitoring.
A key secondary efficacy end point was the occurrence of 
5-point (5P)-major adverse coronary events (MACE; cardio-
vascular death, nonfatal MI, nonfatal stroke, recurrent ischemia 
requiring hospitalization, or urgent coronary revascularization) 
up to 30 and 90 days. Other secondary efficacy end points 
included individual components of the composite 5P-MACE 
end point and stent thrombosis up to 30 and 90 days, ex vivo 
platelet aggregation and pharmacokinetics.
An independent clinical events committee, blinded to treat-
ment assignment, adjudicated all suspected bleeding events 
and efficacy end point events identified by investigators or trig-
gered by monitoring procedures according to predefined and 
standardized criteria utilizing patient medical records/source 
documentation (see Data Supplement for further details). In 
particular, a diagnosis of nonfatal or PCI-related (within 48 
hours) MI was made by applying the Third Universal Definition 
of MI21 to documented clinical evidence (symptoms, ECG 
changes, angiography, or imaging) and cTnI concentrations 
(local or central lab value determined using a conventional non-
high sensitivity assay). In addition to all of the planned, pre-
determined end points listed above, an exploratory post hoc 
ischemic end point included 30-day MACE plus the occurrence 
of myocardial injury within 48 hours defined by increasing lev-
els of cTnI (>99th percentile URL threshold(s)21) in absence 
of ischemic, angiographic or imaging findings as defined by 
the Third Universal Definition of MI. An independent data and 
safety monitoring board oversaw the individual and collective 
safety of the patients in the study by reviewing unadjudicated 
bleeding events, efficacy end point events, and other adverse 
events through 90 days.
Pharmacokinetics and Pharmacodynamics
Two clinical sites possessing the capability to perform light trans-
mittance aggregometry participated in the pharmacokinetics/
pharmacodynamics substudy to assess platelet function and 
measure plasma drug concentrations in randomized patients. 
Blood samples were collected at predose, 0.5 hours, 1 hour, 2 
hours, 4 to 6 hours, 24 hours or discharge (same day), and 14 
days after initiation of study drug. Research laboratory techni-
cians, blinded to treatment allocation, measured ex vivo inhibition 
of platelet aggregation induced by multiple agonists in recalci-
fied platelet-rich plasma derived from whole blood samples 
anticoagulated with sodium citrate (0.4% final) and EDTA (eth-
ylenediaminetetraacetic acid; 0.25 mmol/L final) as described.15 
Whole blood samples collected in EDTA for plasma separation 
were quantified for PZ-128 by an ultra-high performance liquid 
chromatography-tandem mass spectrometric method.15
Statistical Analysis
TRIP-PCI was designed as a proof-of-concept phase 2 trial to 
estimate the bleeding risk of the PZ-128 pepducin on top of 
standard aspirin and P2Y12 inhibitor therapy in patients under-
going cardiac catheterization ± PCI. Power calculations were 
used to evaluate the size of noninferiority margins that could 
be detected using the assumption that the incidence of major 
plus minor bleeding among placebo-treated subjects would 
range from 2% to 6% (Data Supplement). Safety data were 
summarized and analyzed as treated, which included random-
ized patients who received any amount of study drug (n=97). 
Efficacy data (MACE and stent thrombosis) were summarized 
by intention-to-treat, which included randomized patients with 
at least one outcome assessment (n=98). The post hoc efficacy 
evaluation of MACE plus myocardial injury using cTnI was ana-
lyzed by a modified intention-to-treat analysis, which included 
randomized patients who underwent cardiac catheterization ± 
PCI and received any amount of study drug and had sufficient 
cTnI biomarker data available to assess cTnI event status from 
baseline up to 48 hours (n=95). The Kaplan-Meier analysis of 
MACE plus myocardial injury at 90 days was performed using a 
modified intent-to-treat population, which included randomized 
patients with at least one follow-up end point in the high-risk 
CAD/ACS subgroup (n=85). Pharmacokinetics (n=20) and 
pharmacodynamics (platelet aggregation; n=56) data were 
summarized and analyzed as treated among the pharmacoki-
netics/pharmacodynamics substudy population. Baseline char-
acteristics were summarized and analyzed by intention-to-treat 
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Student t test or Mann-Whitney U test was used to compare 
continuous variables between groups, and the Fisher exact 
test was used to compare the categorical variables between 
2 groups. Differences between the changes of parameters 
were analyzed using 2-way repeated-measures ANOVA 
mixed-effects models with Bonferroni post hoc test correction. 
Logistic regression adjusted for age and total coronary ath-
erosclerotic burden (total lesions of ≥50% stenosis) was used 
to compare the relative risks in the post hoc efficacy analysis 
where a nominal P≤0.05 was considered statistically signifi-
cant. The Kaplan-Meier cumulative event probability over time 
was used for the MACE plus myocardial injury events plot, and 
the Gehan-Breslow-Wilcoxon test was used to produce the 
hazard ratio and associated P value. For platelet aggregation, 
repeated measures, 2-way ANOVA mixed-effects models, with 
dose of PZ-128 and time (global P value) and between group 
comparisons with placebo (P value versus 0.0 mg/kg) were 
conducted. Statistical analyses were performed using SAS ver-
sion 9.3 (SAS Institute Inc, Cary, NC).
RESULTS
Study Design and Dose Selection in the TRIP-
PCI Trial
The trial was a parallel-group, multicenter, randomized, 
double-blind, placebo-controlled phase 2 study. The 
study used one recruitment stage to simultaneously 
evaluate safety at 2 dose levels of PZ-128 (0.3 and 0.5 
mg/kg; Figure 2) which were expected to produce ample 
pharmacodynamic target engagement on PAR1 based 
on the previous phase 1 experience using ex vivo platelet 
aggregation assays.15
Patient Characteristics in the TRIP-PCI Trial
The TRIP-PCI trial enrolled 100 patients presenting for 
nonemergent cardiac catheterization and meeting crite-
ria for eligibility as defined by the protocol (Data Supple-
ment) across 3 clinical sites in the United States. The first 
patient was randomized and dosed on May 27, 2016, and 
the final patient was dosed on February 19, 2018, with 
last follow-up contact on May 25, 2018. Patients were 
assigned to receive PZ-128 0.3 mg/kg (n=35), PZ-128 
0.5 mg/kg (n=31), and placebo (n=34; Figure 2). Of 
the 100 patients randomized, 97 (97%) received the 
entire 2-hour infusion of PZ-128 (0.3 or 0.5 mg/kg) or 
placebo and underwent the index cardiac catheteriza-
tion procedure (Figure 2). Two patients (2%) withdrew 
consent to participate in the trial immediately after ran-
domization before dosing due to reconsideration. One 
patient (1%) experienced an adverse event shortly after 
randomization, was not dosed with the Investigational 
Product (PZ-128 or placebo), and did not undergo car-
diac catheterization but was followed in the trial for 30 
days for intent-to-treat. Of the 97 patients who received 
the Investigational Product infusion and underwent the 
cardiac catheterization, 38 (39%) received a PCI that 
day. Out of the 59 patients who did not undergo PCI, 
11 (11%) patients went on to have surgical intervention 
via CABG within the 90-day duration of the trial. Forty-
eight (49%) received medical management out of which 
3 subsequently ended up getting a PCI between 2-90 
days. There was no unblinding done in any patient for 
CABG or for any reason in the entire study.
The baseline demographics and clinical character-
istics of the study population are shown in Table 1. 
Although there were no significant baseline differences 
between the combined active (0.3 mg/kg + 0.5 mg/
kg) and placebo groups, body mass index was gener-
ally higher in the placebo group, while age, smoking his-
tory, dyslipidemia, and cTnI tended to be higher in the 
active drug pool (Table 1). The proportions of patients 
with an initial diagnosis at presentation of stable angina 
(39%), unstable angina (27%), NSTEMI (19%), and 
other/no angina (eg, positive functional tests; 15%) 
were similar across the groups. Of note, the higher dose 
level of 0.5 mg/kg comprised a higher-risk group with 
26% NSTEMI compared with placebo (18% NSTEMI). 
Although not significant due to the small numbers, there 
were 3-times more diabetics in the 0.3 mg/kg PZ-128 
group compared with the 0.5 mg/kg PZ-128 group but 
almost twice as many NSTEMI in the 0.5 mg/kg PZ-128 
group compared with the 0.3 mg/kg PZ-128 group. The 
average TIMI risk score among the 46 patients with ACS 
was 3.4±1.3 with 70% having a moderately high-risk 
score of 3 to 4. The index diagnostic angiography was 
successfully completed in all dosed patients with 88% 
performed via radial arterial access (Table 2). Overall, 
the number of lesions with ≥50% stenosis averaged 2.9 
(range 0–12) per patient with the PZ-128 group having 
a higher average (3.1 versus 2.5 placebo) as well as 
proportion of individuals with ≥5 lesions (31% versus 
17% placebo). The duration of the entire cardiac cath-
eterization ± PCI was similar across dose groups with 
a median time of 32 minutes. The procedure typically 
ended 1 hour before the blinded Investigational Product 
infusion was completed. More than half of the patients 
had dual antiplatelet therapy (52/97, 54%) during the 
index hospitalization and were routinely discharged on 
antiplatelet therapy (95%) with 39% aspirin only and 
56% dual antiplatelet therapy (favoring clopidogrel 31% 
versus ticagrelor/prasugrel 25%).
Primary and Secondary Safety Outcomes
The primary end point of the study, namely the incidence 
of TIMI major plus minor bleeding was 1.0% (1/97) 
among all patients: 1.6% (1/62) in the PZ-128-treated 
patients and 0% (0/35) in placebo-treated patients and 
was not significantly different (Table 3). There were no 
fatal or major bleeding events or transfusions. There was 
one minor bleed at the arterial access site in the PZ-128 
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dose (0.5 mg/kg) PZ-128 arm. The incidence of TIMI 
minimal bleeding (secondary safety end point) was 2.1% 
(2/97)—one occurred in the 0.3 mg/kg dose group and 
the other at 0.5 mg/kg, with no bleeding observed in the 
placebo cohort. CABG was performed on 11 patients 
ranging from 2 to 51 days, and in 5 patients within 14 
days of receiving study drug (Table 2). There were no 
CABG-related TIMI major bleeding events (0/11) or 
transfusions required in any patient (0/97). Median 
24-hour chest tube drainage in CABG patients was 
similar between active PZ-128 (425 mL) and placebo 
groups (420 mL), as was the total drainage (605 and 
745 mL, respectively, Table 3).
Secondary and Exploratory Efficacy Outcomes
The overall incidence of the predetermined secondary 
end point of MACE—cardiovascular death, MI (non-
fatal), stroke (nonfatal), recurrent ischemia requiring 
hospitalization, or urgent coronary revascularization—
at 30 days according to dose group were 5.9% pla-
cebo (2/34) and 0% (0/64) PZ-128 group (P=0.13), 
and at 90 days they were 6.1% (2/33) placebo and 
1.6% (1/62) PZ-128 (P=0.29; Table I in the Data 
Supplement). There was no stent thrombosis (0/37) 
during the trial.
As shown in the exploratory end point post hoc anal-
ysis of Figure 3, PZ-128 was associated with numeri-
cally less MACE plus myonecrosis events (Table I in 
the Data Supplement) among high-risk CAD (diabetes, 
smoking, prior MI) and NSTE-ACS patients (unstable 
angina + NSTEMI), patients with positive baseline car-
diac biomarkers (NSTEMI/elevated baseline cTnI) and 
older patients (age ≥75 years). In the high-risk CAD 
plus ACS patient group (n=83), there were 8/27=30% 
events in the placebo arm versus 14/56 events=25% 
in the combined 0.3+0.5 mg/kg PZ-128 dose group 
(adjusted relative risk [RR]=0.89 [95% CI, 0.44–1.9]; 
Figure 2. Trial profile.
CABG indicates coronary artery bypass grafting; and PCI, percutaneous coronary intervention. *Transient ischemic attack (exclusion criteria) 
before start of study drug caused cardiac catheterization procedure to be canceled, and patient was followed for 30 d as part of the intent-
to-treat population (efficacy). †Patient included in safety analysis for placebo group (n=35). ‡These 32 patients include the one patient† that 
incorrectly received placebo. §Of the 35 patients assigned to 0.3 mg/kg PZ-128, 2 patients withdrew consent, leaving 33 patients who 
completed 30-d follow-up. ∥Thrombolysis in myocardial infarction major plus minor bleeding as treated. #Major adverse cardiac events and 
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P=0.77). Event rates occurring in the individual high-risk 
groups of patients with diabetes, smoking, or prior MI 
ranged from 22% to 29% in the placebo group versus 
7% to 17% in the combined drug group, an RR=0.29 
to 0.32 (P=0.29–0.32). The ACS subjects (n=42) had 
a placebo event rate of 43% and PZ-128 event rate 
of 32% (RR=0.89 [95% CI, 0.39–2.0]; P=0.77). The 
NSTEMI patients (n=15) had a placebo event rate of 
80% versus 40% in the PZ-128 group (RR=0.23 [95% 
CI, 0.04–1.2]; P=0.08).
Analysis of the subgroup of patients with elevated 
baseline cTnI values (n=19) comprised mainly of patients 
with NSTEMI, showed that the placebo group had 83% 
(5/6) events versus 31% (4/13) events in the com-
bined PZ-128 group, an RR=0.14 (95% CI, 0.02–0.75; 
P=0.02; Figure 3). In patients ≥75 years old, there was an 
RR=0.17 (95% CI, 0.03–1.04; P=0.06) for the PZ-128 
cohort (1/8 events) versus placebo (3/4 events).
Figure 4 shows the Kaplan-Meier estimates of the 
time-to-event for MACE/myonecrosis for the placebo 




PZ-128, 0.3 mg/kg 
(n=35)
PZ-128, 0.5 mg/kg 
(n=31)
PZ-128 pooled, 0.3/ 
0.5 mg/kg (n=66)
Demographics
 Age, y 59 (12) 62 (11) 63 (9) 63 (10)
 Age ≥65 y 10 (29%) 17 (49%) 14 (45%) 31 (47%)
 Weight, kg 103 (20) 98 (13) 95 (18) 96 (15)
 Body mass index, kg/m2 33.4 (5.2) 32.0 (4.6) 31.3 (5.5) 31.7 (5.0)
 Body mass index ≥30 kg/m2 28 (82%) 23 (66%) 18 (58%) 41 (62%)
 Male sex 27 (79%) 33 (94%) 24 (77%) 57 (86%)
 White race* 30 (88%) 29 (83%) 30 (97%) 59 (89%)
Presentation characteristics
 Indication for cardiac catheterization
   Non–ST-segment–elevation acute coronary 
syndrome
15 (44%) 15 (43%) 16 (52%) 31 (47%)
   NSTEMI 6 (18%) 5 (14%) 8 (26%) 13 (20%)
   Unstable angina 9 (26%) 10 (29%) 8 (26%) 18 (27%)
  Stable angina 12 (35%) 15 (43%) 12 (39%) 27 (41%)
  Other, no angina 7 (21%) 5 (14%) 3 (10%) 8 (12%)
Cardiovascular risk factors
 Hypertension 30 (88%) 28 (80%) 22 (71%) 50 (76%)
 Dyslipidemia 28 (82%) 32 (91%) 29 (94%) 61 (92%)
 Smoker (former or current) 17 (50%) 24 (69%) 22 (71%) 46 (70%)
 Diabetes 11 (32%) 15 (43%) 4 (13%) 19 (29%)
Cardiovascular disease history
 Previous MI 9 (27%) 7 (20%) 7 (23%) 14 (21%)
 Previous PCI or CABG 12 (35%) 13 (37%) 10 (32%) 23 (35%)
Baseline risk assessment
 TIMI risk score for unstable angina/NSTEMI 3.4 (1.5) 3.4 (0.9) 3.3 (1.4) 3.3 (1.2)
 Elevated cardiac troponin I† 6 (18%) 7 (21%; n=33) 9 (29%) 16 (25%; n=64)
Periprocedural medications for index catheterization‡
 Aspirin (81–325 mg) 35 (100%) 30 (97%) 31 (100%) 61 (98%)
 P2Y12 inhibitor loading
  Clopidogrel 6 (17%) 4 (13%) 3 (10%) 7 (11%)
  Ticagrelor or prasugrel 7 (20%) 7 (22%) 8 (26%) 15 (24%)
 Unfractionated heparin 14 (40%) 12 (39%) 12 (39%) 24 (39%)
 Glycoprotein IIb/IIIa inhibitor (thrombotic bailout) 2 (6%) 0 0 0
Data are n (%) or mean (SD). There were no significant differences between placebo and PZ-128 groups.
CABG indicates coronary artery bypass grafting; MI, myocardial infarction; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary 
intervention; and TIMI, Thrombolysis In Myocardial Infarction.
*Race was self-reported.
†Defined as serum/plasma concentration >0.03 ng/mL.
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versus combined PZ-128 treatment groups in the high-
risk CAD/ACS patients (n=85) over 90 days. There was 
a nonsignificant decrease in hazard ratio=0.81 (95% CI, 
0.32–2.1), P=0.61 of a MACE/myonecrosis event in the 
PZ-128-treated cohorts versus placebo over 90 days. 
The majority of the events occurred in the first 24 hours 
due to the overall dominance of myocardial injury/necro-
sis based on elevations of cTnI detected during the peri-
procedural period shortly after cardiac catheterization ± 
PCI. While most of the benefit of PZ-128 occurred in 
the first 30 days, the difference from placebo was main-
tained at 90 days.
Platelet Aggregation and Pharmacokinetics of 
PZ-128
PZ-128 at a dose of 0.5 mg/kg provided significant 
(P<0.01) inhibition of final platelet aggregation to PAR1 
agonist, 5 μmol/L SFLLRN, at 2 hours (end of infusion) 
and at 24 hours/discharge, and to 20 μmol/L SFLLRN 











Intravenous study drug administered completely 35 (100%) 31 (100%) 31 (100%) 62 (100%)
Arterial access
 Radial 31 (89%) 26 (84%) 28 (90%) 54 (87%)
 Femoral 4 (11%) 3 (10%) 3 (10%) 6 (10%)
 Both radial and femoral 0 2 (6%) 0 2 (3%)
Distribution of coronary lesions
 None with ≥50% stenosis 13 (37%) 7 (23%) 9 (29%) 16 (26%)
 Single-vessel disease 6 (17%) 6 (19%) 6 (19%) 12 (19%)
 Double-vessel disease 7 (20%) 7 (23%) 8 (26%) 15 (24%)
 Triple-vessel disease 9 (26%) 11 (35%) 8 (26%) 19 (31%)
Location of diseased vessels with ≥50% stenosis*
 Left main 2 (6%) 2 (7%) 3 (10%) 5 (8%)
 Proximal LAD 7 (20%) 10 (32%) 6 (19%) 16 (26%)
 Middle/distal LAD, diagonal branches 16 (46%) 16 (52%) 17 (55%) 33 (53%)
 Circumflex, OMs, LPDA, LPL branches 14 (40%) 18 (58%) 12 (39%) 30 (48%)
 RCA, RPDA, RPL, AM branches 12 (34%) 17 (55%) 15 (48%) 32 (52%)
 Ramus 3 (8%) 0 2 (6%) 2 (3%)
No. of lesions with ≥50% stenosis per patient 2.5 (2.8) 3.4 (3.0) 2.7 (2.9) 3.1 (3.0)
Management strategy recommended from diagnostic angiography
 PCI 14 (40%) 12 (39%) 13 (42%) 25 (40%)
 CABG 4 (11%) 5 (16%) 5 (16%) 10 (16%)
 Medical management or none 17 (49%) 14 (45%) 13 (42%) 27 (44%)
Index PCI undertaken 14 (40%) 12 (39%) 12 (39%) 24 (39%)
 PCI on native vessel 13 (93%) 11 (92%) 10 (83%) 21 (88%)
 PCI on coronary graft 1 (7%) 1 (8%) 2 (17%) 3 (12%)
No. of lesions treated per patient 1.4 (0.6) 1.7 (0.8) 1.4 (0.7) 1.5 (0.7)
Stent implanted 14 (40%) 12 (39%) 11 (35%) 23 (37%)
 DES 13 (93%) 11 (92%) 11 (100%) 22 (96%)
 Biodegradable polymer DES 1 (7%) 1 (8%) 0 1 (4%)
 BMS 0 0 0 0
 No. of stents implanted per patient 1.4 (0.5) 2.3 (1.7) 1.3 (0.8) 1.8 (1.4)
CABG performed within 90 d 3 (8%) 3 (10%) 5 (16%) 8 (13%)
 No. of CABG within 14 d 2 1 2 3
Data are n (%), mean (SD) for patients as treated (n=97). 
AM indicates acute marginal; BMS, bare metal stent; CABG, coronary artery bypass grafting; DES, drug-eluting stent; LAD, left anterior 
descending; LPDA, left posterior descending artery; LPL, left posterolateral; OM, obtuse marginal; PCI, percutaneous coronary interven-
tion; RCA, right coronary artery; RPDA, right posterior descending artery; and RPL, right posterolateral.
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at 24 hours/discharge (P<0.001) compared with placebo 
(Figure 5A, Table II in the Data Supplement). Onset of inhi-
bition of PAR1 showed 34% mean inhibition of platelet 
aggregation to 5 μmol/L SFLLRN by the end of the 2 
hours infusion and peak inhibition of 61% by 24 hours/
discharge. The inhibitory effects of PZ-128 were dose-
dependent with lower mean inhibition of platelet aggrega-
tion to 5 μmol/L SFLLRN at 1 hour through 14-day time 
points in the 0.3 mg/kg group as compared to the 0.5 mg/
kg group. Inhibition of PAR1 by PZ-128 was reversible 
with 50% recovery of aggregation at 14 days (32% inhi-
bition of platelet aggregation) relative to 24 hours (61% 
inhibition of platelet aggregation) in the 0.5 mg/kg dose 
group (Figure 5A). At the high PAR1 agonist concentra-
tion of 20 μmol/L SFLLRN, there was 61% recovery of 
aggregation by 14 days (14%) relative to 24 hours (36%) 
with 0.5 mg/kg PZ-128 (Table II in the Data Supplement). 
PZ-128 was specific for PAR1 with no significant effects 
on aggregation to any other platelet agonists to the ADP, 
PAR4 and collagen receptors as compared to placebo 
(Figure 5B and 5C, Table II in the Data Supplement). The 
mean PZ-128 plasma concentrations in each treatment 
group are shown in Figure 5D, and a summary of the phar-
macokinetic parameters of PZ-128 is presented in Table 
III in the Data Supplement. Peak drug levels were pro-
portional to dose and occurred at the end of the 2 hours 
infusion in both PZ-128 dose levels with a terminal t1/2 of 
elimination of 1.20 to 1.31 hours. PZ-128 was undetect-
able in plasma at the 24-hour and 14-day time points.
Additional Safety and Tolerability Outcomes 
Measured by Adverse Events
PZ-128 was well tolerated at both dose levels with 
no observed allergic drug reactions. Most frequently 
reported treatment-emergent adverse events occurring 
in the combined PZ-128 groups through 30 days were 
oral paresthesia, hypotension, and pruritic rash. There 
were no significant differences between the PZ-128 and 
placebo groups with respect to routine clinical laboratory 
assessments, vital signs, or ECG parameters.
DISCUSSION
PZ-128 is a first-in-class, cell-penetrating, membrane-
tethered pepducin that targets the intracellular surface 
of PAR1 to prevent coupling with G proteins. In TRIP-
PCI, we showed that PZ-128 was well tolerated and did 
not cause a significant elevation in bleeding in CAD/
ACS patients undergoing cardiac catheterization ± 
PCI even when administered on top of dual antiplatelet 
drugs (aspirin and P2Y12 inhibitor) and heparin. Like-
wise, there was no elevated bleeding observed in the 
patients that underwent CABG instead of PCI after 
receiving PZ-128. Although this phase 2 study was not 
powered to specifically detect clinical efficacy, a poten-
tial reduction in MACE plus myocardial injury events at 
30 days was noted in the PZ-128 cohort relative to pla-
cebo in patients who had elevated baseline cTnI levels 
(ie, NSTEMI), in a post hoc analysis.
Contrary to thrombin inhibitors (bivalirudin, hirudin, 
argatroban, and dabigatran), PAR1 antagonists do not 
interfere with the procoagulant activity of thrombin cleav-
age of fibrinogen.22 Because thrombin-dependent fibrin 
generation is largely unaffected by inhibition of PAR1, 
a thrombin-receptor antagonist should be safer a priori 
than a thrombin inhibitor22,23 in treating arterial thrombo-
sis. PZ-128 did not prevent initial platelet adhesion to 
exposed collagen surfaces but prevented large occlusive 
thrombi from forming.24 PZ-128 significantly suppressed 




PZ-128, 0.3 mg/kg 
(n=31)
PZ-128, 0.5 mg/kg 
(n=31)
PZ-128 pooled, 0.3/ 
0.5 mg/kg (n=62)
Any bleeding event 0 2 (6%) 1 (3%) 3 (5%)
Primary safety outcome*
 TIMI major or minor bleeding 0 1 (3%) 0 1 (2%)
  TIMI major bleeding 0 0 0 0
  TIMI minor bleeding 0 1 (3%) 0 1 (2%)
Secondary safety outcomes*
 TIMI minimal bleeding 0 1 (3%) 1 (3%) 2 (3%)
 TIMI CABG bleeding† 0 0 0 0
Other outcomes
 Transfusion, any 0 0 0 0
 CABG chest tube drainage, mL 745 (598–829) 1020 465 (395–535) 605 (465–813)
Data are n (%) or median (IQR) and are presented for all patients (n=97), as treated. All bleeding events are non-CABG related unless 
otherwise indicated. There were no significant differences based on the Fisher exact test. 
CABG indicates coronary artery bypass grafting; IQR, interquartile range; and TIMI, Thrombolysis In Myocardial Infarction.
*Based on adjudicated data.
†TIMI CABG-related bleeding is defined as major bleeding. Six patients underwent CABG within 30 days of study drug treatment (3 in the 
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platelet aggregation to PAR1 agonist, SFLLRN, at 2- 
to 24-hour time points in TRIP-PCI but did not inhibit 
aggregation to PAR4, ADP, or collagen agonists. These 
findings suggest that PZ-128 can permit the forma-
tion of initial platelet monolayer necessary for control of 
bleeding but block pathological thrombus propagation 
that occurs at the site of plaque rupture or iatrogenic 
endothelial denudation. Furthermore, synergistic pro-
tective effects against carotid artery thrombosis using 
dual therapy of PZ-128 plus clopidogrel was shown 
previously in guinea pig.14 Similar to these findings, the 
PAR1 inhibitor SCH 602539 was shown to synergisti-
cally inhibit thrombosis in a Folts model in monkeys in 
combination with the P2Y12 inhibitor cangrelor.
25 These 
synergistic effects between PAR1 and P2Y12 were pre-
dicted by platelet functional studies showing that PAR1 
preferentially contributes to shape change, calcium flux 
and early GPIIb-IIIa activation, whereas P2Y12 stabilizes 
the high affinity state of GPIIb-IIIa leading to irrevers-
ible aggregation.4,26 Therefore, inhibiting both pathways 
should have a strong synergistic protective effect in 
PCI patients. In this regard, there was an extra 15% to 
38% inhibition of ADP-dependent aggregation at the 4 
to 6 hours and 24-hour time points in the 0.5 mg/kg 
PZ-128 versus placebo groups yielding nearly complete 
inhibition (95%) of mean final ADP aggregation at the 
24-hour point relative to placebo (60%) This indicates 
synergism of ADP platelet inhibition with dual antiplate-
let therapy (PZ-128/P2Y12 inhibitor) on top of aspirin 
in the periprocedural time window. This extra synergism 
on ADP inhibition was not observed in recent studies 
with the Food and Drug Administration-approved dose 
(2.08 mg) of vorapaxar at even up to 30 days of repeat 
administration.13
Despite the critical importance of PAR1 in mediat-
ing platelet-thrombosis and myocardial ischemia, there 
are no approved PAR1 inhibitors for the treatment 
of NSTE-ACS (unstable angina, NSTEMI), STEMI, or 
patients undergoing PCI. The orally active vorapaxar was 
approved in the United States as an adjunctive treatment 
for the secondary prevention of atherothrombotic events 
in patients with prior MI or peripheral arterial disease 
Figure 3. Stratified analysis of major adverse cardiac events (MACE) plus myocardial injury at 30 d across subgroups.
A 5P-MACE is defined as a composite of death from cardiovascular causes, nonfatal myocardial infarction (MI), nonfatal stroke, recurrent 
ischemia with hospitalization, or urgent coronary revascularization. Myocardial injury is defined as an elevation of cTnI (cardiac troponin I) of 
>5×99% URL (>0.14 ng/mL) in patients with a normal baseline cTnI (<0.028 ng/mL) or >20% increase above an elevated baseline cTnI 
according to the Third Universal Definition of Myocardial Infarction. Analysis was performed in a modified intent-to-treat population which 
comprised randomized patients who underwent cardiac catheterization ± percutaneous coronary intervention (PCI) and received any amount 
of investigational product and had adequate cTnI research biomarker data available for evaluation (n=95). Solid box width is proportional to 
number of patients in subgroup. Adjusted relative risk (RR) with 95% CI and P values adjusted for age and total coronary atherosclerotic 
burden (29-segment CASS [Coronary Artery Surgery Study]) using logistic regression (LR). Prior MI did not regress by LR, and χ2 analysis 
was used instead. P value for age ≥75 was adjusted only for CASS score in the LR model. Diabetes includes prediabetes. Smoking includes 
former and current. Elevated cTnI patients were those patients with a diagnosis of NSTEMI (non–ST-segment–elevation myocardial infarction) 
determined by the clinical site before randomization and index catheterization plus additional patients whose elevated cTnI levels were identified 
from the central research lab baseline sample in the absence of local clinical biomarker assessment. ACS indicates acute coronary syndromes; 
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and no history of stroke. The TRACER study (Throm-
bin Receptor Antagonist for Clinical Event Reduction 
in Acute Coronary Syndrome) investigated the ability of 
vorapaxar to reduce 5P-MACE on top of standard anti-
platelet therapy in patients with high-risk NSTE-ACS.12 
In TRACER, vorapaxar significantly reduced the risk of 
the secondary end point of cardiovascular death, MI, 
or stroke. However, there was a significant increase in 
moderate and severe bleeding with vorapaxar compared 
with placebo, including intracerebral hemorrhage.12 
The effects of vorapaxar in preventing the composite 
of cardiovascular death, MI, stroke, or urgent coronary 
revascularization in stable patients with established ath-
erothrombotic disease was assessed in the Thrombin 
Receptor Antagonist TRA 2°P-TIMI 50 study.11 In TRA 
2°P-TIMI 50, the original primary end point of cardio-
vascular death, MI, stroke, or recurrent ischemia lead-
ing to revascularization was significantly reduced in the 
vorapaxar group versus placebo as was the reordered 
primary end point of 3-year cardiovascular death, MI, or 
stoke. Again, there was an increased risk of moderate or 
severe bleeding and increased rate of intracerebral hem-
orrhage in the vorapaxar group.11 These data suggested 
that while vorapaxar is effective at reducing ischemic 
outcomes in a broad population of patients with acute 
and chronic atherothrombosis in combination with other 
antiplatelet therapy (eg, aspirin and P2Y12), this comes 
with the cost of an increased risk of clinically signifi-
cant bleeding, due in large part to the extremely long ≥4 
weeks pharmacodynamic half-life of vorapaxar. The abil-
ity to rapidly and reversibly inhibit PAR1 signaling by an 
intravenous strategy such as PZ-128 would be an ideal 
in the high-risk patient undergoing cardiac intervention 
and may translate into a superior reduction in adverse 
thrombotic event occurrence. For the highest risk 
groups, namely patients with NSTEMI and STEMI, who 
may derive the largest clinical benefit from a fast-acting 
reversible PAR1 agent, the routine use of the strongest 
antiplatelet drugs, namely intravenous GPIIb/IIIa inhibi-
tors,27 is no longer recommended in combination with 
heparin, due to a less clear benefit in the modern era of 
more effective ADP receptor (P2Y12) antagonists, safer 
interventional techniques (ie, radial approach), and the 
associated significant increase in bleeding risk.5
In support of the notion that PAR1 may play an addi-
tional role in mediating cardiac ischemic injury, post 
hoc efficacy analysis of 30-day MACE plus myocardial 
injury events in the subgroup of patients with elevated 
Figure 4. Kaplan-Meier plot for major adverse cardiac events (MACE) plus myocardial injury over 90 d.
Kaplan-Meier curves show the cumulative incidence of 5P-MACE plus myocardial injury through 90 d of follow-up after treatment with study 
drug. The efficacy analysis was conducted in coronary artery disease (CAD) patients with high-risk features or acute coronary syndrome (ACS) 
who underwent cardiac catheterization ± percutaneous coronary intervention (PCI) and received the study drug as an adjunct to standard 
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baseline cTnI values showed a potential treatment 
effect for PZ-128 with RR=0.14 (95% CI, 0.02–0.75, 
P=0.02) compared with placebo. This positive effect 
could be due to a type 1 error due to the low num-
ber of patients, however, all of the other high-risk sub-
group analyses (high-risk CAD+ACS; ACS; NSTEMI; 
diabetes; smoking; prior MI; age ≥75) also showed a 
relative risk reduction of a MACE+myocardial injury 
event which favors PZ-128 over placebo (with P values 
ranging from 0.06 to 0.89). Indeed, PAR1 has been 
shown to directly mediate myocardial ischemia/reper-
fusion injury28,29 and cardiac remodeling and hypertro-
phy30 in rodent models of MI which lack PAR1 on their 
platelets. PAR1-deficiency reduced dilation of the left 
A B
C D
Figure 5. Inhibition of platelet aggregation and pharmacokinetics in TRIP-PCI (Thrombin Receptor Inhibitory Pepducin in 
Percutaneous Coronary Intervention) patients.
Ex vivo aggregation was conducted in platelet-rich plasma by light transmission aggregometry and final aggregation at 7 min normalized 
to baseline (t=0) for each patient. Inhibition of platelet aggregation (mean±SD) for the placebo (n=20), 0.3 mg/kg PZ-129 (n=19), and 
0.5 mg/kg (n=17) cohorts was determined for (A) 5 µmol/L PAR1 (protease-activated receptor 1) agonist peptide, SFLLRN, (B) 5 µmol/L 
ADP (adenosine diphosphate), (C) 160 µmol/L PAR4 agonist peptide, AYPGKF. The global P value was determined by repeated-measures 
2-way ANOVA, **P<0.01 for 0.5 mg/kg PZ-128 vs placebo. D, Plasma levels of PZ-128 in the 3 dose cohorts were determined by mass 
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ventricle and improved left ventricular function after 
ischemia/reperfusion injury similar to PZ-128 but had 
no effect on scar formation at 2 weeks.30 It is possi-
ble that infarct differences at 2 hours may not be the 
same at 2 weeks or longer in rodents and humans, 
to be examined in future studies with PZ-128. Com-
plete genetic deficiency of PAR1 may have effects on 
cardiovascular function in mice including 50% embry-
onic lethality at E12.5, and potential compensation 
on hemodynamic effects in surviving animals, which 
could account for differences in wound healing pro-
cesses that occur over chronic time periods.31 Strande 
et al28 demonstrated that treatment with SCH79797 
before or during ischemia significantly reduced infarct 
size associated with ischemia/reperfusion injury in rat. 
The PAR1 inhibitor also attenuated left ventricular dila-
tion and improved left ventricular systolic function of 
reperfused rat myocardium at 28 days with a decrease 
in scar size.29 Overall, these findings indicate both 
platelet-dependent and independent effects of PAR1 
inhibitors that could potentially translate into reduced 
cardiac events.
This was a proof-of-concept study in 100 patients 
undergoing cardiac catheterization ± PCI that was pri-
marily intended to show safety and evaluate bleeding 
risk of intravenous PZ-128 pepducin on top of stan-
dard-of-care antiplatelet therapies. A limitation was the 
bleeding rate was extremely low (0%–1.6%), in part, 
due to the high use of standard-of-care radial access 
(88%). Therefore, the study was not sufficiently pow-
ered for formal testing of noninferiority for the primary 
end point at 30 days (would require >600 patients) 
or to detect clinically meaningful differences in TIMI 
bleeding events between treatment groups. Given the 
small numbers of NSTEMI subjects in TRIP-PCI, a 
larger study that includes a high proportion of NSTEMI 
subjects will be needed to validate whether PZ-128 
can confer a potential dual benefit in protecting against 
cardiac ischemia/acute myocardial injury along with 
suppressing thrombus formation in patients presenting 
with more significant coronary disease. It is noteworthy 
that patients with acute myocardial injury according the 
Third or Fourth Universal Definition of MI have a com-
parable rate of cardiovascular death or MI at 1 year as 
patients with type 1 MI (14%–17%) due to occlusive 
ischemic events.32
In conclusion, the favorable initial safety profile, and 
potentially protective effects against myocardial isch-
emia/necrosis associated with PZ-128 indicates that the 
TRIP-PCI intervention provides the basis for additional 
clinical trials. Establishing rapid and reversible recep-
tor blockade with a parenterally administered PAR1 
blocker may translate into a superior reduction in adverse 
post-PCI thrombotic event occurrence with acceptable 
bleeding. Pepducins, as exemplified by PZ-128, there-
fore represent a new approach to modulating signal 
transduction from the inside surface of the cell, poten-
tially expanding the scope of GPCR therapeutics to treat 
a much wider range of severe and life-threatening ill-
nesses, such as acute arterial thrombosis.
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